

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PROPOSED CHANGE OF NAME

The Board proposes to change the name of the Company from “China Pharmaceutical Group Limited 中國製藥集團有限公司” to “CSPC Pharmaceutical Group Limited 石藥集團有限公司”. The Proposed Change is subject to approval by the Shareholders by way of special resolution at the EGM and confirmation by the Registrar of Companies in Hong Kong.

A circular containing further details of the Proposed Change, together with a notice convening the EGM, will be despatched to the Shareholders as soon as practicable.

PROPOSED CHANGE OF NAME

The board of directors (the “**Board**”) of China Pharmaceutical Group Limited (the “**Company**”) proposes to change the name of the Company from “China Pharmaceutical Group Limited 中國製藥集團有限公司” to “CSPC Pharmaceutical Group Limited 石藥集團有限公司” (the “**Proposed Change**”).

CONDITIONS FOR THE PROPOSED CHANGE OF NAME

The Proposed Change will become effective subject to the satisfaction of all of the following conditions:—

1. the approval by the shareholders of the Company (the “**Shareholders**”) by way of special resolution at the extraordinary general meeting of the Company to be convened for such purpose (the “**EGM**”); and
2. the issuance of the certificate of incorporation on change of name by the Registrar of Companies in Hong Kong confirming the Proposed Change.

Further announcement will be made by the Company upon the Proposed Change becoming effective.

REASON FOR THE PROPOSED CHANGE OF NAME

The Company is an investment holding company and, through its subsidiaries (together the “Group”), is principally engaged in the manufacture and sales of pharmaceutical products. The Group has been using the brand name of  石药集团 for its products for many years which is now a well-known brand in the PRC. The Board considers that the proposed new name of the Company, which resembles such brand name, will better reflect the business presence of the Group in the PRC and further permeate the brand name of the Group at all levels.

EFFECT OF THE PROPOSED CHANGE OF NAME

The Proposed Change will not affect the rights of any Shareholder. All existing share certificates of the Company in issue bearing the existing name of the Company will, after the Proposed Change becoming effective, continue to be valid evidence of legal title to the shares of the Company and will continue to be valid for trading, settlement and delivery purposes.

GENERAL

A circular containing further details of the Proposed Change, together with a notice convening the EGM, will be despatched to the Shareholders as soon as practicable.

There will not be any arrangement for free exchange of existing share certificates of the Company for new share certificates under the proposed new name of the Company.

By order of the Board
CAI Dongchen
Chairman

Hong Kong, 18 January 2013

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. FENG Zhenying, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. ZHAO John Huan, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin and Mr. WANG Zhenguo as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. HUO Zhenxing, Mr. QI Moujia, Mr. GUO Shichang, Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo and Mr. ZHANG Fawang as independent non-executive directors.